Systematic review and meta-analysis of the efficacy of biologic and targeted synthetic therapies in sarcoidosis.

ABSTRACT:

Objectives

Infliximab, an anti-TNF agent, is used to treat sarcoidosis that does not respond to corticosteroids or second-line agents. The efficacy of other anti-TNF agents, non-TNF biologics and targeted synthetic therapies remains unclear. This study aims to evaluate the role of these therapies in the management of multisystem sarcoidosis.

Methods

We conducted a systematic literature search to identify trials of biological and targeted synthetic therapies in sarcoidosis. Meta-analyses examined %-predicted forced vital capacity (FVC), as mean change from baseline. Heterogeneity was measured using the I² statistic. Vote counting based on the direction of effect, as recommended by the Cochrane network, was used to synthesise study estimates.

Results

The sear

SUBMITTER: Bechman K 

PROVIDER: S-EPMC12505053 | biostudies-literature | 2025 Sep

REPOSITORIES: biostudies-literature